Kyowa Kirin Secures Public Reimbursement for Burosumab in Four Canadian Provinces for Adult XLH

A longstanding coverage gap for adult patients with X-linked hypophosphatemia closes in Canada as Kyowa Kirin confirms public reimbursement of CRYSVITA® (burosumab injection) across Ontario, British Columbia, Saskatchewan, and Alberta, and through the federal Non-Insured Health Benefits (NIHB) program. Until now, publicly funded access was restricted to pediatric patients under active bone growth — leaving adults, for whom XLH continues to progress, reliant on private insurance or out-of-pocket costs.

The listings follow pan-Canadian Pharmaceutical Alliance (pCPA) negotiations that produced a letter of intent, after which Kyowa Kirin worked with individual jurisdictions to advance formulary inclusion. For market access and reimbursement teams, the sequencing is instructive: a single pCPA negotiation outcome does not automatically trigger provincial listings, and the company's public call for remaining participating provinces and territories to list the product signals that formulary uptake remains incomplete across the country.

XLH is a rare genetic disorder driven by elevated FGF23 activity, which impairs renal phosphate reabsorption and active vitamin D synthesis, resulting in progressive bone and muscle pathology throughout a patient's lifetime. Burosumab, a recombinant fully human monoclonal IgG1 antibody, inhibits FGF23 directly and is indicated for patients six months of age and older. The adult indication has carried Health Canada approval, but reimbursement policy had not kept pace with the clinical label — a misalignment that the current formulary additions begin to correct.

For medical affairs and health economics teams operating in rare disease, the case reinforces the operational reality that post-approval reimbursement advocacy requires sustained, jurisdiction-by-jurisdiction engagement even after a national negotiation concludes. The NIHB listing extends coverage to federally insured populations, adding a distinct access pathway that sits outside provincial drug plan structures and carries its own submission and listing requirements.

Kyowa Kirin has indicated it will continue pressing the provinces and territories that participated in pCPA negotiations but have not yet listed the product, making the current reimbursement footprint an interim milestone rather than a resolved access picture.

Source: Kyowa Kirin Canada via GlobeNewswire, 6 May 2026.